6-Chloro-2-methyl-2H-indazol-5-amine CAS 1893125-36-4 Tsarkake>98.0% (LCMS) Ensitrelvir (S-217622) Matsakaici COVID-19

Takaitaccen Bayani:

Suna: 6-Chloro-2-methyl-2H-indazol-5-amine

Saukewa: 1893125-36-4

Tsafta:> 98.0% (LCMS)

Bayyanar: Haske Brown zuwa Grey Solid Powder

Matsakaicin Ensitrelvir (S-217622), COVID-19

Kyakkyawan inganci, Samar da Kasuwanci

E-Mail: alvin@ruifuchem.com

Aika mana imel

Cikakken Bayani

Samfura masu dangantaka

Tags samfurin

Bayani:

Kasuwancin Kasuwanci Ensitrelvir (S-217622) Matsakaici:
S-Ethylisothiourea Hydrobromide CAS 1071-37-0
2,4,5-Trifluorobenzyl Bromide CAS 157911-56-3
Trimethyloxonium Tetrafluoroborate CAS 420-37-1
6-Chloro-2-methyl-2H-indazol-5-amine CAS 1893125-36-4
3- (Chloromethyl) -1-methyl-1H-1,2,4-triazole hydrochloride CAS 135206-76-7
1,3,5-Triazine-2,4 (1H,3H) -dione, 3- (1,1-dimethylethyl) -6- (ethylthio) - CAS 1360105-53-8

Abubuwan Sinadarai:

Sunan Sinadari	6-Chloro-2-methyl-2H-indazol-5-amin
Lambar CAS	1893125-36-4
Lambar CAT	Saukewa: RF-PI1506
Matsayin Hannun jari	A Stock
Tsarin kwayoyin halitta	Saukewa: C8H8ClN3
Nauyin Kwayoyin Halitta	181.62
Alamar	Ruifu Chemical

Ƙayyadaddun bayanai:

Abu	Ƙayyadaddun bayanai
Bayyanar	Haske Brown zuwa Grey Solid Foda
Tsarkake / Hanyar Bincike	98.0% (LCMS)
1 H NMR Spectrum	Daidaita Da Tsarin
LCMS	Daidaita Da Tsarin
Asara akan bushewa	≤1.00%
Jimlar ƙazanta	<2.00%
Matsayin Gwaji	Matsayin Kasuwanci
Amfani	Matsakaicin Ensitrelvir (S-217622), COVID-19

Kunshin & Ajiya:

Kunshin: kwalban, 25kg/Drum, ko bisa ga abokin ciniki ta bukata.

Yanayin Ajiya:Ajiye a cikin kwantena da aka rufe a wuri mai sanyi da bushe;Kare daga haske da danshi.

Amfani:

FAQ:

Aikace-aikace:

6-Chloro-2-methyl-2H-indazol-5-amine (CAS: 1893125-36-4) matsakaici ne na Ensitrelvir (S-217622).Ensitrelvir na Shionogi & Co. magani ne na rigakafi mai inganci wanda ke aiki kamar Pfizer's Paxlovid.Oral Xocova (Ensitrelvir), wanda ke da tsarin aiki iri ɗaya kamar Pfizer's Paxlovid (Nirmatrelvir + Ritonavir), ya bambanta da cewa yana buƙatar ɗaukar sau ɗaya kawai a rana, yayin da tasirin warkewa na ensitrelvir ba ze zama ƙasa da Paxlovid ba.A matsayin tunatarwa, ana gudanar da Nirmatrelvir sau biyu a kowace rana, tare da mai ƙarfafawa wanda Ritonavir ke wakilta.Ensitrelvir ya zama kwaya ta farko ta Jafananci don kula da COVID-19, na uku da aka amince da shi bisa ka'ida a Japan;a watan Fabrairun 2022.